CALCITRIOL: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal Pharms	CALCITRIOL	calcitriol	CAPSULE;ORAL	203289	ANDA	Amneal Pharmaceuticals LLC	65162-519-03	30 CAPSULE in 1 BOTTLE (65162-519-03)	2017-06-18
Amneal Pharms	CALCITRIOL	calcitriol	CAPSULE;ORAL	203289	ANDA	Amneal Pharmaceuticals LLC	65162-519-10	100 CAPSULE in 1 BOTTLE (65162-519-10)	2017-06-18
Amneal Pharms	CALCITRIOL	calcitriol	CAPSULE;ORAL	203289	ANDA	Amneal Pharmaceuticals LLC	65162-519-25	250 CAPSULE in 1 BOTTLE (65162-519-25)	2017-06-18
Amneal Pharms	CALCITRIOL	calcitriol	CAPSULE;ORAL	203289	ANDA	Amneal Pharmaceuticals LLC	65162-576-03	30 CAPSULE in 1 BOTTLE (65162-576-03)	2017-06-18
Amneal Pharms	CALCITRIOL	calcitriol	CAPSULE;ORAL	203289	ANDA	Amneal Pharmaceuticals LLC	65162-576-10	100 CAPSULE in 1 BOTTLE (65162-576-10)	2017-06-18
Amneal Pharms	CALCITRIOL	calcitriol	CAPSULE;ORAL	203289	ANDA	Amneal Pharmaceuticals LLC	65162-576-25	250 CAPSULE in 1 BOTTLE (65162-576-25)	2017-06-18
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the current landscape of Calcitriol suppliers, focusing on active pharmaceutical ingredient (API) manufacturers and key formulation companies. The analysis highlights market concentration, patent expiries, and potential supply chain vulnerabilities for this Vitamin D analog.

Who Are the Primary API Manufacturers for Calcitriol?

The global production of Calcitriol API is concentrated among a limited number of manufacturers, primarily located in India and China. These companies operate under stringent Good Manufacturing Practices (GMP) and hold Drug Master Files (DMFs) with regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key API suppliers include:

Teva Pharmaceutical Industries Ltd.: While a major player in finished dosage forms, Teva also has significant API manufacturing capabilities.
Sun Pharmaceutical Industries Ltd.: A large Indian pharmaceutical company with a broad API portfolio, including calcitriol.
Dr. Reddy's Laboratories Ltd.: Another prominent Indian API producer with global reach.
Zydus Lifesciences Ltd. (formerly Cadila Healthcare): A diversified Indian pharmaceutical group manufacturing various APIs.
An H-Pharma: A Chinese manufacturer known for its generic APIs.

These manufacturers supply Calcitriol API to both generic drug companies and some branded pharmaceutical firms. Production capacity and regulatory compliance are critical differentiators in this segment. For instance, manufacturers must adhere to specific impurity profiles and enantiomeric purity requirements as outlined in pharmacopoeias such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP).

What Are the Key Formulation and Dosage Forms of Calcitriol?

Calcitriol is formulated into several dosage forms to meet diverse therapeutic needs. The most common forms are oral capsules and injectable solutions.

Oral Formulations:

Capsules: Typically available in strengths of 0.25 mcg and 0.5 mcg. Brands like Rocaltrol (Valeant Pharmaceuticals International, Inc. – now Bausch Health Companies Inc.) were historically significant. Generic versions are widely available.
Oral Solutions: Less common but available, offering flexibility in dosing, particularly for pediatric patients or those with swallowing difficulties.

Injectable Formulations:

Intravenous (IV) Solutions: Administered in hospital settings for patients undergoing dialysis or with severe conditions. Strengths vary, commonly ranging from 1 mcg/mL to 2 mcg/mL.

Companies actively involved in formulating and marketing Calcitriol finished products include:

Bausch Health Companies Inc.: Through its acquisition of Valeant, Bausch Health inherited the legacy Rocaltrol brand and its associated market presence.
Fresenius Medical Care AG & Co. KGaA: A major provider of renal care services, Fresenius also markets calcitriol formulations for its dialysis patients.
Various Generic Manufacturers: Numerous companies, including those listed as API suppliers, also market generic calcitriol capsules and injections globally. Examples include Mylan (now Viatris Inc.), Sandoz (a division of Novartis), and Apotex Inc.

The choice of formulation is driven by the intended route of administration, patient population, and the specific indication being treated. Bioavailability and stability are key considerations in formulation development.

What is the Patent Landscape for Calcitriol?

Calcitriol, as a synthesized form of the active vitamin D metabolite, has a long history and its foundational patents have long expired. The original patents covering the discovery and synthesis of calcitriol were filed in the early to mid-1970s.

Key patent-related milestones:

Original Composition of Matter Patents: Expired in the late 1980s or early 1990s.
Formulation and Method of Use Patents: While the molecule itself is off-patent, secondary patents related to specific novel formulations, improved delivery systems, or new therapeutic uses may have existed or could still be in force for certain niche applications. However, these are generally not broad enough to prevent generic competition for the standard indications.

The absence of strong patent protection for the core molecule means that the market for Calcitriol is largely driven by generic competition. This has led to significant price erosion over time. Any active patents would likely pertain to specific advanced drug delivery systems or novel combination therapies rather than the calcitriol molecule itself. Companies seeking to differentiate in this space often focus on enhanced patient convenience or improved pharmacokinetic profiles through proprietary formulations.

How Does Regulatory Status Impact Supply?

Regulatory approval is a critical determinant of supply for Calcitriol. Manufacturers must obtain marketing authorizations from health authorities in each target market.

Key Regulatory Considerations:

FDA (U.S.): Calcitriol is available as both branded (e.g., Rocaltrol) and generic products. The FDA reviews DMFs for APIs and approves New Drug Applications (NDAs) for branded products and Abbreviated New Drug Applications (ANDAs) for generics. Compliance with Current Good Manufacturing Practices (cGMP) is mandatory.
EMA (Europe): Similar to the FDA, the EMA evaluates calcitriol products through centralized or national procedures. Marketing Authorisation Applications (MAAs) are required.
Other Jurisdictions: Approval processes vary by country but generally require evidence of quality, safety, and efficacy.

The regulatory pathway significantly influences market entry for new suppliers. Companies must invest heavily in generating and maintaining the extensive documentation required for regulatory submissions. Any disruption in regulatory compliance, such as a warning letter from the FDA or a recall due to quality issues, can immediately halt supply to a market. For instance, a manufacturing site failing an FDA inspection can lead to import alerts and a complete cessation of product supply for that manufacturer.

What Are the Supply Chain Risks and Mitigation Strategies for Calcitriol?

The Calcitriol supply chain, like many in the pharmaceutical industry, faces several inherent risks. The concentrated nature of API manufacturing, geopolitical factors, and quality control failures are primary concerns.

Identified Risks:

Geographic Concentration of API Manufacturing: A significant portion of Calcitriol API production is based in India and China. This concentration creates vulnerability to regional disruptions such as natural disasters, trade disputes, or sudden regulatory changes in these countries.
Quality Control and GMP Compliance Failures: Any lapse in GMP standards by an API or finished product manufacturer can lead to product recalls, supply interruptions, and reputational damage. Regulatory actions, such as FDA Form 483 observations or import bans, can severely impact availability.
Raw Material Sourcing: The synthesis of Calcitriol involves specific precursor chemicals. Disruptions in the supply of these precursors, whether due to manufacturing issues or market demand, can impact overall API production.
Logistics and Distribution: Global shipping delays, customs issues, and cold chain maintenance (if applicable for certain formulations) can affect the timely delivery of both API and finished products.
Generic Price Pressures: Intense competition in the generic calcitriol market can lead to razor-thin margins, potentially impacting the financial viability of some suppliers and reducing their ability to invest in supply chain resilience.

Mitigation Strategies:

Supplier Diversification: Companies should aim to qualify and maintain relationships with multiple GMP-certified API manufacturers across different geographic regions. This reduces reliance on any single supplier or country.
Robust Quality Agreements: Implementing comprehensive quality agreements with suppliers is essential. These agreements should clearly define specifications, testing requirements, change control procedures, and audit rights.
Inventory Management: Maintaining strategic safety stocks of critical APIs and finished products can buffer against short-term supply disruptions. However, this must be balanced against the cost of inventory and product shelf life.
Supply Chain Mapping and Transparency: Gaining visibility into the upstream supply chain, including the sources of key raw materials, helps identify potential vulnerabilities further down the line.
Scenario Planning and Business Continuity: Developing contingency plans for various disruption scenarios (e.g., natural disasters, geopolitical events, regulatory actions) allows for a more agile response.
Auditing and Supplier Qualification: Regular and thorough audits of all supply chain partners are critical to ensure ongoing compliance with quality and regulatory standards.

Conclusion

The Calcitriol market is characterized by a mature, genericized landscape with a consolidated API manufacturing base. While the molecule itself is off-patent, market access and supply stability are dictated by stringent regulatory compliance and robust supply chain management. Pharmaceutical companies and investors must carefully assess the risks associated with supplier concentration and quality control to ensure consistent product availability and mitigate potential market disruptions.

Key Takeaways

Calcitriol API manufacturing is concentrated among a few global players, primarily in India and China.
The core patents for Calcitriol have expired, leading to a highly competitive generic market.
Regulatory compliance, particularly adherence to cGMP, is paramount for all suppliers.
Supply chain risks include geographic concentration, quality failures, and raw material availability.
Diversification of API sources and robust quality agreements are critical mitigation strategies.

Frequently Asked Questions

Are there any new patents on Calcitriol that could impact generic entry? While patents on the Calcitriol molecule itself have long expired, there might be patents covering novel formulations, specific delivery devices, or new therapeutic uses. However, these are unlikely to prevent the market entry of standard generic capsules or injections.
What are the typical lead times for sourcing Calcitriol API? Lead times for Calcitriol API can range from 8 to 16 weeks, depending on the supplier, order volume, and current market demand. This can be extended by regulatory review periods or significant quality deviations.
How do regulatory inspections affect Calcitriol supply? Regulatory inspections (e.g., by the FDA or EMA) are critical. A failed inspection can lead to import alerts, product recalls, and a complete halt in supply for that manufacturer, significantly impacting market availability.
What is the average cost difference between branded and generic Calcitriol? Generic Calcitriol is typically 30-70% less expensive than its branded counterpart. This price difference is a direct result of the competitive generic market and the absence of patent exclusivity.
What are the primary indications for Calcitriol that drive demand? The primary indications for Calcitriol are secondary hyperparathyroidism in patients with chronic kidney disease, hypocalcemia in patients undergoing chronic renal dialysis, and certain forms of rickets and osteomalacia. Demand is largely tied to the prevalence of these conditions, particularly chronic kidney disease.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-file-drug-information-recall-manufacturing/drug-master-files-dmfs [2] European Medicines Agency. (n.d.). Guidance on applications. Retrieved from https://www.ema.europa.eu/en/how-we-work/documents-guidance-policy/guidance-documents/applications [3] United States Pharmacopeia. (n.d.). USP-NF. Retrieved from https://www.usp.org/products/usp-nf [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia-2 [5] Bausch Health Companies Inc. (2023). Annual Report. [6] Fresenius Medical Care AG & Co. KGaA. (2023). Annual Report. [7] Sandoz. (n.d.). Product Portfolio. Retrieved from https://www.sandoz.com/our-business/our-products [8] Viatris Inc. (2023). Annual Report. [9] Apotex Inc. (n.d.). Product Catalog. Retrieved from https://www.apotex.com/

Suppliers and packagers for generic pharmaceutical drug: CALCITRIOL

CALCITRIOL

Calcitriol Drug Supply Chain Analysis